旨在评估人乳头瘤病毒 (HPV) 疫苗对感染 HPV 的韩国女性队列的有效性。从 2010 年到 2021 年，诊断出 HPV 阳性、意义不明的非典型鳞状细胞或低度鳞状上皮内病变的 20-60 岁韩国女性接受了从6家医院招募。通过观察接种组和未接种组之间病理和临床信息以及实验结果（患病率、病毒载量（VL）、身体状态（PS）和 HPV16/18 感染持续时间）的差异来评估 HPV 疫苗的有效性。 HPV16/18 患病率在 1,757 名登记的队列女性中，疫苗接种率从 14.3% 增加到 60.7%，而疫苗接种率从 18.5% 下降到 11.8%。对从参与者收集的 96 个样本进行的 DNA 分析表明，HPV 疫苗接种使 HPV16 VL 降低了 6 倍，并且 HPV16 和 HPV18 的 E2/E6 比率分别增加了 1.4 倍和 5 倍。通过疫苗接种，HPV16感染率（持续时间超过18个月的从31.0%降至21.6%）和HPV18感染率（持续时间超过12个月且少于24个月的从35.5%降至21.1%）。我们发现VL和感染持续时间成正比。此外，HPV疫苗接种不仅将持续性组和清除组的VL降低至1/4，而且将HPV16的持续性率从90%（27/30）降低至70.6%（12/17）。HPV疫苗接种降低了患病率和清除率。 HPV16 和 HPV18 的感染持续时间并使 PS 保持游离形式。未接种疫苗组中持续性 VL 高于清除率的趋势表明，疫苗降低 HPV16 VL 的作用可能会通过缩短感染持续时间来降低进展为宫颈癌的风险。© 2024。亚洲妇科肿瘤学会、韩国学会日本妇科肿瘤学会和日本妇科肿瘤学会。

To evaluate human papillomavirus (HPV) vaccine effectiveness in a cohort of Korean women infected with HPV.From 2010 to 2021, Korean women aged 20-60 years who diagnosed HPV-positive atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion were recruited from 6 hospitals. HPV vaccine effectiveness was estimated by observing the differences in pathological and clinical information and experimental results-prevalence, viral load (VL), physical state (PS), and HPV16/18 infection duration-between the vaccinated and unvaccinated groups.HPV16/18 prevalence declined from 18.5% to 11.8% as vaccination rates increased from 14.3% to 60.7% in the 1,757 registered cohort women. DNA analysis from 96 samples collected from the participants, indicated that HPV vaccination reduced HPV16 VL by 6 times and increased E2/E6 ratio for both HPV16 and HPV18 by 1.4 and 5 times, respectively. The HPV16 infection rate-lasting more than 18 months from 31.0% to 21.6%-and the HPV18 infection rate-lasting more than 12 and less than 24 months from 35.5% to 21.1%-were reduced by vaccination. We found VL and the infection duration to be directly proportional. Moreover, HPV vaccination reduced not only the VL to 1/4 in both the persistence and clearance groups but also the persistence rate from 90% (27/30) to 70.6% (12/17) in HPV16.HPV vaccination reduced the prevalence and duration of infection and kept the PS in an episomal form for both HPV16 and HPV18. The tendency of persistence VL to be higher than clearance in the unvaccinated group implies that the vaccine's effect of reducing VL in HPV16 may lower the risk of progression to cervical cancer by shortening the infection duration.© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.